Quarterly report · Q1
4574.TEDINET S100TDKT
Period2024-01-01 → 2024-03-31
Filed2024-05-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.4bn | 2024-01-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥6.1bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.2bn | 2023-01-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | ¥214m | 2024-01-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | −¥155m | 2023-01-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥229m | 2024-01-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.2bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥242m | 2023-01-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥429m | 2024-01-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥242m | 2023-01-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥472m | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥3.6bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥243m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥472m | 2024-01-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | −¥243m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥13.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥13.2bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥14.4bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.6bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥6.5bn | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.5bn | at 2023-12-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥9.41 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-76.25 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.59 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 57.1% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.0% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-03-31 | −¥207m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥140m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥140m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥64m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥1m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥1m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | segment profit | 2024-01-01 → 2024-03-31 | −¥2m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥1.2bn |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥1.2bn |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥489m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-03-31 | ¥421m |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-03-31 | −¥241m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥259m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥259m |
| jpcrp040300-q1r_E22560-000Infection Control Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥124m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥1m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥1m |
| jpcrp040300-q1r_E22560-000Other Business Linesreportable segment | segment profit | 2023-01-01 → 2023-03-31 | −¥5m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥906m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥906m |
| jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥215m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-01-01 → 2023-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-01-01 → 2023-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-01-01 → 2023-03-31 | ¥85m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 353
| Item | Context | Value | Unit |
|---|---|---|---|
| Profit loss attributable to owners of parent | Prior1YTDDuration | -243000000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 472000000 | JPY |
| Profit loss | Prior1YTDDuration | -243000000 | JPY |
| Profit loss | CurrentYTDDuration | 472000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | － | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | 94000000 | JPY |
| Foreign currency translation adjustment net of tax oci | Prior1YTDDuration | 8000000 | JPY |
| Foreign currency translation adjustment net of tax oci | CurrentYTDDuration | 57000000 | JPY |
| Other comprehensive income | Prior1YTDDuration | 8000000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 152000000 | JPY |
| Comprehensive income | Prior1YTDDuration | -234000000 | JPY |
| Comprehensive income | CurrentYTDDuration | 624000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | -234000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 624000000 | JPY |
| Write downs of inventories | Prior1YTDDuration | -40000000 | JPY |
| Write downs of inventories | CurrentYTDDuration | 28000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 906000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | 259000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | 1000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1167000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 1167000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 906000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | 259000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | 1000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1167000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 1167000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 215000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | -124000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | -5000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 85000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -241000000 | JPY |
| Operating income | Prior1YTDDuration | -155000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | 1236000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | 140000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | 1000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1377000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 1377000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E22560-000InfectionControlBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E22560-000OtherBusinessLinesReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |